Hypoparathyroidism clinical trials at University of California Health
2 in progress, 0 open to eligible people
Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
Sorry, in progress, not accepting new patients
This study is investigating the safety and efficacy of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (cHP). During the first 24 weeks of the trial, participants will be randomized to receive eneboparatide or placebo. Study treatment is blinded: patients and doctors will not know which group each patient has been randomized to. All patients will start with a fixed dose of study treatment (eneboparatide or placebo), administered subcutaneously with a pre-filled pen. Study treatment will be individually titrated. After completion of the first 24 weeks, patients will be treated in the open label extension part of the study for 132 weeks. During this phase, all patients (including patients that were in the placebo group) will receive eneboparatide.
at UCLA
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
Sorry, not yet accepting patients
This study is being done to see if transplanting parathyroid tissue into the forearm will help hypo-parathyroid patients achieve parathyroid hormone (PTH) levels that would help normalize their serum calcium and phosphorus levels. The parathyroid tissue used in this study will come from cadaveric tissues that were donated at the time of the death of the donor(s).
at UCSF
Our lead scientists for Hypoparathyroidism research studies include Peter Stock, MD, PhD.
Last updated: